Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2807)
All Articles published online
|
May 7, 2007 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Le Guillou-Guillemette H, Vallet S, Gaudy-Graffin C, Payan C, Pivert A, Goudeau A, Lunel-Fabiani F. Genetic diversity of the hepatitis C virus: Impact and issues in the antiviral therapy. World J Gastroenterol 2007; 13(17): 2416-2426 [PMID: 17552024 DOI: 10.3748/wjg.v13.i17.2416] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i17/2416.htm |
| Number | Citing Articles |
| 1 |
Rachel Abraham, Banumathi Ramakrishna, Avinash Balekuduru, Hubert Darius J. Daniel, Priya Abraham, C. Eapen Eapen, George Kurian. Clinicopathological features and genotype distribution in patients with hepatitis C virus chronic liver disease. Indian Journal of Gastroenterology 2009; 28(2): 53 doi: 10.1007/s12664-009-0018-z
|
| 2 |
Yasir Waheed. Effect of interferon plus ribavirin therapy on hepatitis C virus genotype 3 patients from Pakistan: Treatment response, side effects and future prospective. Asian Pacific Journal of Tropical Medicine 2015; 8(2): 85 doi: 10.1016/S1995-7645(14)60193-0
|
| 3 |
Ahmed A. Al-Qahtani, George Kessie, Damian Dela Cruz, Faleh Z. Al-Faleh, Mohammed N. Al-Ahdal. Quasispecies of genotype 4 of hepatitis C virus genomes in Saudi patients managed with interferon alfa and ribavirin therapy. Annals of Saudi Medicine 2010; 30(2): 109 doi: 10.4103/0256-4947.60515
|
| 4 |
Cíntia Bittar, Ana Carolina Gomes Jardim, Lilian Hiromi Tomonari Yamasaki, Claudia Márcia Aparecida Carareto, João Renato Rebello Pinho, Philippe Lemey, Isabel Maria Vicente Guedes de Carvalho-Mello, Paula Rahal, Michael Alan Polis. On Hepatitis C Virus Evolution: The Interaction between Virus and Host towards Treatment Outcome. PLoS ONE 2013; 8(4): e62393 doi: 10.1371/journal.pone.0062393
|
| 5 |
Juliet A. Shenge, Georgina N. Odaibo, David O. Olaleye, Jason Blackard. Phylogenetic analysis of hepatitis C virus among HIV/ HCV co-infected patients in Nigeria. PLOS ONE 2019; 14(2): e0210724 doi: 10.1371/journal.pone.0210724
|
| 6 |
Shanmugam Saravanan, Vijayakumar Velu, Nagalingeswaran Kumarasamy, Esaki Muthu Shankar, Subhadra Nandakumar, Kailapuri G. Murugavel, Pachamuthu Balakrishnan, Sunil Suhas Solomon, Suniti Solomon, Sadras Panchatcharam Thyagarajan. The prevalence of hepatitis B virus and hepatitis C virus infection among patients with chronic liver disease in South India. International Journal of Infectious Diseases 2008; 12(5): 513 doi: 10.1016/j.ijid.2008.02.006
|
| 7 |
Muhammad Ahmad Maqbool, Mohamed R. Imache, Martin R. Higgs, Sophie Carmouse, Jean-Michel Pawlotsky, Hervé Lerat. Regulation of Hepatitis C Virus Replication by Nuclear Translocation of Nonstructural 5A Protein and Transcriptional Activation of Host Genes. Journal of Virology 2013; 87(10): 5523 doi: 10.1128/JVI.00585-12
|
| 8 |
Chikako Yamamoto, Shintaro Nagashima, Channarena Chuon, Ko Ko, Son Huy Do, Oline Lim, Sirany Hok, Somana Svay, Junko Matsuo, Keiko Katayama, Kazuaki Takahashi, Junko Tanaka. Substitution of the CD81 Binding Site and β-Sandwich Area in E2 of HCV in Cambodia. Viruses 2020; 12(5): 551 doi: 10.3390/v12050551
|
| 9 |
Cíntia Bittar, Ana Carolina G Jardim, Lilian HT Yamasaki, Artur TL de Queiróz, Claudia MA Carareto, João Renato R Pinho, Isabel Maria VG de Carvalho-Mello, Paula Rahal. Genetic diversity of NS5A protein from hepatitis C virus genotype 3a and its relationship to therapy response. BMC Infectious Diseases 2010; 10(1) doi: 10.1186/1471-2334-10-36
|
| 10 |
Claire Gondeau, Lydiane Pichard-Garcia, Patrick Maurel. Cellular models for the screening and development of anti-hepatitis C virus agents. Pharmacology & Therapeutics 2009; 124(1): 1 doi: 10.1016/j.pharmthera.2009.05.010
|
| 11 |
Steven Roger, Alexandra Ducancelle, Hélène Le Guillou-Guillemette, Catherine Gaudy, Françoise Lunel. HCV virology and diagnosis. Clinics and Research in Hepatology and Gastroenterology 2021; 45(3): 101626 doi: 10.1016/j.clinre.2021.101626
|
| 12 |
Jan Paeshuyse, Inge Vliegen, Lotte Coelmont, Pieter Leyssen, Oriana Tabarrini, Piet Herdewijn, Harald Mittendorfer, Johnny Easmon, Violetta Cecchetti, Ralf Bartenschlager, Gerhard Puerstinger, Johan Neyts. Comparative In Vitro Anti-Hepatitis C Virus Activities of a Selected Series of Polymerase, Protease, and Helicase Inhibitors. Antimicrobial Agents and Chemotherapy 2008; 52(9): 3433 doi: 10.1128/AAC.01534-07
|
| 13 |
Kieran Maheden, Brendan Todd, Calvin J. Gordon, Egor P. Tchesnokov, Matthias Götte. Viral Replication Enzymes and their Inhibitors Part A. The Enzymes 2021; 49: 315 doi: 10.1016/bs.enz.2021.07.002
|
| 14 |
Sagarika Das, Devyashree Medhi, Anjan Jyoti Talukdar, Dina Raja, Kishore Sarma, Anisha Sarma, Lahari Saikia. Hepatitis C virus genotypes among population with reported risk factors in Assam, north-east India: Emergence of genotype-8. The Indian Journal of Medical Research 2024; 160: 43 doi: 10.25259/ijmr_1222_23
|
| 15 |
Qing Ge, John J Xu, David M Evans, A James Mixson, Harry Y Yang, Patrick Y Lu. Leveraging Therapeutic Potential of Multi-Targeted Sirna Inhibitors. Future Medicinal Chemistry 2009; 1(9): 1671 doi: 10.4155/fmc.09.131
|
| 16 |
Phyllis T. Losikoff, Alyssa A. Self, Stephen H. Gregory. Dendritic cells, regulatory T cells and the pathogenesis of chronic hepatitis C. Virulence 2012; 3(7): 610 doi: 10.4161/viru.21823
|
| 17 |
|
| 18 |
Pierina D’Angelo, Rossana Celeste Jaspe, Carmen Luisa Loureiro, Cristina Gutiérrez, María Zulay Sulbarán, Yoneira Sulbarán, Felix Toro, Flor Helene Pujol. Desempeño de métodos moleculares para la identificación de subtipos poco comunes del virus de hepatitis C genotipo 2. Biomédica 2018; 38(2): 282 doi: 10.7705/biomedica.v38i0.3864
|
| 19 |
Vinod K Rustgi. Safety of small molecules in combination with interferon-based therapy for hepatitis C virus. Expert Opinion on Drug Safety 2010; 9(6): 883 doi: 10.1517/14740338.2010.495942
|
| 20 |
Fernando González-Candelas, F Xavier López-Labrador. Clinical Relevance of Genetic Heterogeneity in HCV. Future Virology 2010; 5(1): 33 doi: 10.2217/fvl.09.63
|
| 21 |
Moataza H. Omran, Wael Nabil, Samar S. Youssef, Mervat El-Sayed, Mostafa K. El Awady. Heterogeneity and New Epitopes of Hepatitis C Virus Genotype 4. Hepatitis Monthly 2013; 13(8) doi: 10.5812/hepatmon.10521
|
| 22 |
Guilherme Rodrigues Fernandes Campos, Cíntia Bittar, Ana Carolina Gomes Jardim, Jacqueline Farinha Shimizu, Mariana Nogueira Batista, Eder Ramos Paganini, Letícia Ribeiro de Assis, Christopher Bartlett, Mark Harris, Vanderlan da Silva Bolzani, Luis Octavio Regasini, Paula Rahal. Hepatitis C virus in vitro replication is efficiently inhibited by acridone Fac4. Journal of General Virology 2017; 98(7): 1693 doi: 10.1099/jgv.0.000808
|
| 23 |
Sandra Ciesek, Thomas Hahn. Relevance of Resistance Against Direct Acting Antiviral Agents in Hepatitis C Virus Infection – What Technology do we Really Need in Clinical Practice?. Current Hepatitis Reports 2013; 12(4): 195 doi: 10.1007/s11901-013-0185-3
|
| 24 |
Samer S. El-Kamary. International Encyclopedia of Public Health. 2025; : 561 doi: 10.1016/B978-0-323-99967-0.00075-2
|
| 25 |
Philippe Halfon, Stephen Locarnini. Hepatitis C virus resistance to protease inhibitors. Journal of Hepatology 2011; 55(1): 192 doi: 10.1016/j.jhep.2011.01.011
|
| 26 |
Andrea Galli, Jens Bukh. Viral Fitness and Evolution. Current Topics in Microbiology and Immunology 2023; 439: 237 doi: 10.1007/978-3-031-15640-3_7
|
| 27 |
Hui-Mei Lin, Jing-Chyi Wang, Han-Shu Hu, Pei-Shan Wu, Wen-Hung Wang, Su-Ying Wu, Chi-Chen Yang, Teng-Kuang Yeh, Tsu-An Hsu, Weir-Torn Jiaang, Yu-Sheng Chao, Jyh-Haur Chern, Andrew Yueh. Resistance Studies of a Dithiazol Analogue, DBPR110, as a Potential Hepatitis C Virus NS5A Inhibitor in Replicon Systems. Antimicrobial Agents and Chemotherapy 2013; 57(2): 723 doi: 10.1128/AAC.01403-12
|
| 28 |
Ashraf A. Tabll, Khaled Atef, Noha G. Bader El Din, Yasmine S. El Abd, Ahmed Salem, Ahmed A. Sayed, Reham M. Dawood, Moataza H. Omran, Mostafa K. El-Awady. IN VITRONEUTRALIZATION OF HCV BY GOAT ANTIBODIES AGAINST PEPTIDES ENCOMPASSING REGIONS DOWNSTREAM OF HVR-1 OF E2 GLYCOPROTEIN. Journal of Immunoassay and Immunochemistry 2014; 35(1): 12 doi: 10.1080/15321819.2013.779925
|
| 29 |
Sobia Kanwal, Tariq Mahmood. Occurrence of genetic modifications in core, 5′UTR and NS5b of HCV associated with viral response to treatment. Virology Journal 2014; 11(1) doi: 10.1186/1743-422X-11-171
|
| 30 |
Lize Cuypers, Guangdi Li, Pieter Libin, Supinya Piampongsant, Anne-Mieke Vandamme, Kristof Theys. Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1–6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance. Viruses 2015; 7(9): 5018 doi: 10.3390/v7092857
|
| 31 |
Angela M. Lam, Eisuke Murakami, Christine Espiritu, Holly M. Micolochick Steuer, Congrong Niu, Meg Keilman, Haiying Bao, Veronique Zennou, Nigel Bourne, Justin G. Julander, John D. Morrey, Donald F. Smee, David N. Frick, Julie A. Heck, Peiyuan Wang, Dhanapalan Nagarathnam, Bruce S. Ross, Michael J. Sofia, Michael J. Otto, Phillip A. Furman.
PSI-7851, a Pronucleotide of β-
d
-2′-Deoxy-2′-Fluoro-2′-
C
-Methyluridine Monophosphate, Is a Potent and Pan-Genotype Inhibitor of Hepatitis C Virus Replication
. Antimicrobial Agents and Chemotherapy 2010; 54(8): 3187 doi: 10.1128/AAC.00399-10
|
| 32 |
Samia Afzal, Muhammad Idrees, Madiha Akram, Zunaira Awan, Bushra Khubaib, Mahwish Aftab, Zareen Fatima, Sadaf Badar, Abrar Hussain. Mutations in the E2-PePHD region of hepatitis C virus genotype-3a and correlation with response to interferon and ribavirin combination therapy in Pakistani patients. Virology Journal 2010; 7(1) doi: 10.1186/1743-422X-7-377
|
| 33 |
Mozhgan Afrasiabi, Seyed Younes Hosseini, Ramin Yaghobi, Mohammad-Reza Fattahi, Maryam Ardebili, Mahboobeh Khodadad. Analysis of Naturally Occurring Resistant Mutations to Hepatitis C Virus NS3 Protease Inhibitors: A Preliminary Study in South of Iran. Jundishapur Journal of Microbiology 2015; 8(10) doi: 10.5812/jjm.24965
|
| 34 |
M Carrozzo. Oral diseases associated with hepatitis C virus infection. Part 1. sialadenitis and salivary glands lymphoma. Oral Diseases 2008; 14(2): 123 doi: 10.1111/j.1601-0825.2007.01436.x
|
| 35 |
Natalia Echeverría, Pilar Moreno, Juan Cristina. Human Virology in Latin America. 2017; : 333 doi: 10.1007/978-3-319-54567-7_17
|
| 36 |
Jing Xu, Shufeng Liu, Yihui Xu, Po Tien, Guangxia Gao. Identification of the nonstructural protein 4B of hepatitis C virus as a factor that inhibits the antiviral activity of interferon-alpha. Virus Research 2009; 141(1): 55 doi: 10.1016/j.virusres.2009.01.001
|
| 37 |
Hanadi Qashqari, Amany Al-Mars, Adeel Chaudhary, Adel Abuzenadah, Ghazi Damanhouri, Mohammed Alqahtani, Maged Mahmoud, Maysaa El Sayed Zaki, Kaneez Fatima, Ishtiaq Qadri. Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance. Infection, Genetics and Evolution 2013; 19: 113 doi: 10.1016/j.meegid.2013.06.025
|
| 38 |
Myriam Lereau, Chantal Fournier-Wirth, Julie Mayen, Carole Farre, Albert Meyer, Vincent Dugas, Jean-François Cantaloube, Carole Chaix, Jean-Jacques Vasseur, François Morvan. Development of Innovative and Versatile Polythiol Probes for Use on ELOSA or Electrochemical Biosensors: Application in Hepatitis C Virus Genotyping. Analytical Chemistry 2013; 85(19): 9204 doi: 10.1021/ac401941x
|
| 39 |
Reem R Al Olaby, Hassan ME Azzazy. Hepatitis C virus RNA assays: current and emerging technologies and their clinical applications. Expert Review of Molecular Diagnostics 2011; 11(1): 53 doi: 10.1586/erm.10.101
|
| 40 |
Juliana Cristina Santiago Bastos, Marina Aiello Padilla, Leonardo Cardia Caserta, Noelle Miotto, Aline Gonzalez Vigani, Clarice Weis Arns. Hepatitis C virus: Promising discoveries and new treatments. World Journal of Gastroenterology 2016; 22(28): 6393-6401 doi: 10.3748/wjg.v22.i28.6393
|
| 41 |
Paul Klenerman, Karen Fitzmaurice. An update on hepatitis C virus. Clinical Medicine 2015; 15(6): s33 doi: 10.7861/clinmedicine.15-6-s33
|
| 42 |
Suhair M. Abozaid, Mohamed Shoukri, Ahmad Al-Qahtani, Mohammed N. Al-Ahdal. Prevailing genotypes of hepatitis C virus in Saudi Arabia: a systematic analysis of evidence. Annals of Saudi Medicine 2013; 33(1): 1 doi: 10.5144/0256-4947.2013.1
|
| 43 |
Cristina Romero-López, Alfredo Berzal-Herranz. The 5BSL3.2 Functional RNA Domain Connects Distant Regions in the Hepatitis C Virus Genome. Frontiers in Microbiology 2017; 8 doi: 10.3389/fmicb.2017.02093
|
| 44 |
Thi Nhan Le, Tu Bao Ho. Intelligent Information and Database Systems. Lecture Notes in Computer Science 2012; 7196: 377 doi: 10.1007/978-3-642-28487-8_39
|
| 45 |
|
| 46 |
Michael J Sofia. Nucleotide Prodrugs for HCV Therapy. Antiviral Chemistry and Chemotherapy 2011; 22(1): 23 doi: 10.3851/IMP1797
|
| 47 |
Ana CG Jardim, Cíntia Bittar, Renata PA Matos, Lílian HT Yamasaki, Rafael A Silva, João RR Pinho, Roberta M Fachini, Claudia MA Carareto, Isabel MVG de Carvalho-Mello, Paula Rahal. Analysis of HCV quasispecies dynamic under selective pressure of combined therapy. BMC Infectious Diseases 2013; 13(1) doi: 10.1186/1471-2334-13-61
|
| 48 |
Federico Bolcic, Natalia Laufer, Carolina Torres, Lucila Cassino, Rita Reynoso, Jorge Quarleri. Longitudinal analysis of the 5′UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients. Antiviral Research 2012; 95(2): 72 doi: 10.1016/j.antiviral.2012.05.015
|
| 49 |
Hui-Mei Lin, Jing-Chyi Wang, Han-Shu Hu, Pei-Shan Wu, Chi-Chen Yang, Chung-Pu Wu, Szu-Yuan Pu, Tsu-An Hsu, Weir-Torn Jiaang, Yu-Sheng Chao, Jyh-Haur Chern, Teng-Kuang Yeh, Andrew Yueh. Resistance Analysis and Characterization of a Thiazole Analogue, BP008, as a Potent Hepatitis C Virus NS5A Inhibitor. Antimicrobial Agents and Chemotherapy 2012; 56(1): 44 doi: 10.1128/AAC.00599-11
|
| 50 |
Lize Cuypers, Guangdi Li, Christoph Neumann-Haefelin, Supinya Piampongsant, Pieter Libin, Kristel Van Laethem, Anne-Mieke Vandamme, Kristof Theys. Mapping the genomic diversity of HCV subtypes 1a and 1b: Implications of structural and immunological constraints for vaccine and drug development. Virus Evolution 2016; 2(2): vew024 doi: 10.1093/ve/vew024
|
| 51 |
Zaki Maysaa El Sayed, F. A. Mansour, M. F. Ghal, S. B. Abou-Zahra. Evaluation of Interleukin-8 in Hepatitis C Virus Infection: Relation to Combined peg-interferon Ribavirin Response and Genotype 4. Immunological Investigations 2011; 40(1): 29 doi: 10.3109/08820139.2010.508192
|
| 52 |
Michael J. Sofia, Wonsuk Chang, Phillip A. Furman, Ralph T. Mosley, Bruce S. Ross. Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase. Journal of Medicinal Chemistry 2012; 55(6): 2481 doi: 10.1021/jm201384j
|
| 53 |
Michael J. Sofia, Phillip A. Furman, William T. Symonds. Accounts in Drug Discovery. 2010; : 238 doi: 10.1039/9781849731980-00238
|
| 54 |
Robert A. Fridell, Dike Qiu, Chunfu Wang, Lourdes Valera, Min Gao.
Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an
In Vitro
Replicon System
. Antimicrobial Agents and Chemotherapy 2010; 54(9): 3641 doi: 10.1128/AAC.00556-10
|
| 55 |
James Lara, Guoliang Xia, Mike Purdy, Yury Khudyakov. Coevolution of the Hepatitis C Virus Polyprotein Sites in Patients on Combined Pegylated Interferon and Ribavirin Therapy. Journal of Virology 2011; 85(7): 3649 doi: 10.1128/JVI.02197-10
|
| 56 |
Nahla Fadl, Tamer Z. Salem. Hepatitis C genotype 4: A report on resistance‐associated substitutions in NS3, NS5A, and NS5B genes. Reviews in Medical Virology 2020; 30(4) doi: 10.1002/rmv.2120
|
| 57 |
H. Le Guillou-Guillemette, P. Calès, F. Lunel. Actualités sur les co-infections VIH–VHC. Antibiotiques 2008; 10(4): 167 doi: 10.1016/j.antib.2008.08.004
|
| 58 |
Juan-Ramón Larrubia, Elia Moreno-Cubero, Joaquín Miquel, Eduardo Sanz-de-Villalobos. Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control. World Journal of Gastroenterology 2015; 21(12): 3480-3491 doi: 10.3748/wjg.v21.i12.3480
|
| 59 |
Michael J. Sofia, Donghui Bao, Wonsuk Chang, Jinfa Du, Dhanapalan Nagarathnam, Suguna Rachakonda, P. Ganapati Reddy, Bruce S. Ross, Peiyuan Wang, Hai-Ren Zhang, Shalini Bansal, Christine Espiritu, Meg Keilman, Angela M. Lam, Holly M. Micolochick Steuer, Congrong Niu, Michael J. Otto, Phillip A. Furman. Discovery of a β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus. Journal of Medicinal Chemistry 2010; 53(19): 7202 doi: 10.1021/jm100863x
|
| 60 |
S. Justa, R.W. Minz, M. Minz, A. Sharma, S. Anand, A. Das, Y.K. Chawla, V.K. Sakhuja. Serial Measurements of Hepatitis C Viral Load by Real-Time Polymerase Chain Reaction Among Recipients of Living-Donor Renal Transplants: A Short-Term Follow-Up Study From a Single Center. Transplantation Proceedings 2010; 42(9): 3568 doi: 10.1016/j.transproceed.2010.07.102
|
| 61 |
Saori Kawasaki, Tu Bao Ho, Tatsuo Kanda, Osamu Yokosuka, Katsuhiro Takabayashi, Nhan Le. Knowledge, Information, and Creativity Support Systems. Lecture Notes in Computer Science 2011; 6746: 79 doi: 10.1007/978-3-642-24788-0_8
|
| 62 |
Phillip A Furman, Angela M Lam, Eisuke Murakami. Nucleoside Analog Inhibitors of Hepatitis C Viral Replication: Recent Advances, Challenges and Trends. Future Medicinal Chemistry 2009; 1(8): 1429 doi: 10.4155/fmc.09.88
|
| 63 |
Medhat K. Shier, James C. Iles, Mohammad S. El-Wetidy, Hebatallah H. Ali, Mohammad M. Al Qattan, Dimitrios Paraskevis. Molecular characterization and epidemic history of hepatitis C virus using core sequences of isolates from Central Province, Saudi Arabia. PLOS ONE 2017; 12(9): e0184163 doi: 10.1371/journal.pone.0184163
|
| 64 |
Jakovljevic B. Mihajlo, Miјailovic D. Zeljko, Popovska Jovicic D. Biljana, Canovic S. Predrag, Gajovic M. Olgica, Jovanovic R. Mirjana, Petrovic S. Dejan, Milovanovic Z. Olivera, Djordjevic D. Natasa. Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2α + Ribavirine Treated Chronic Hepatitis C Patients. Hepatitis Monthly 2013; 13(6) doi: 10.5812/hepatmon.6750
|
| 65 |
Piyasena Hewawasam, Yong Tu, Min Gao, Umesh Hanumegowda, Jay Knipe, Julie A. Lemm, Dawn D. Parker, Karen L. Rigat, Susan B. Roberts, Nicholas A. Meanwell, John F. Kadow. Discovery and preclinical evaluation of potent, orally bioavailable, metabolically stable cyclopropylindolobenzazepine acylsulfonamides as thumb site 1 inhibitors of the hepatitis c virus NS5B RNA-dependent, RNA polymerase. Bioorganic & Medicinal Chemistry Letters 2016; 26(3): 936 doi: 10.1016/j.bmcl.2015.12.058
|
| 66 |
Natalia Echeverría, Gonzalo Moratorio, Juan Cristina, Pilar Moreno. Hepatitis C virus genetic variability and evolution. World Journal of Hepatology 2015; 7(6): 831-845 doi: 10.4254/wjh.v7.i6.831
|